It is reasonable to contemplate the possibility that if both the sensitivity to platinum and the p53 genetic background of ovarian cancer cells do not condition their response to the growth inhibition activity of mifepristone, such findings would have great clinical relevance. The gene discussed is TP53; the disease is ovarian carcinoma.